Switzerland's Oculis Q3 net loss widens as expenses rise

What happened

Swiss biopharmaceutical company Oculis reported a wider third-quarter net loss as operating expenses rose year over year, driven by higher staffing costs and non-recurring corporate initiatives. The company ended the quarter with $252 in cash and equivalents and said its cash runway extends into the second half of 2029.

Confirmed

Global impact / market context

Rising staffing and corporate costs increase the cash Oculis uses to operate, while its stated runway into the second half of 2029 suggests it expects to fund planned work for now. Trial progress and future results may influence whether spending translates into valuable medicines.

Analyst inference

The article reports clinical milestones and an expected year-end 2026 readout from the Licaminlimab PREDICT-1 trial, alongside ongoing enrollment in the Privosegtor trial. These developments offer potential future catalysts, but neither trial progress nor biomarker findings establish that a treatment will succeed commercially.

Analyst inference

What to watch

1. Watch for the expected Licaminlimab PREDICT-1 topline results around year-end 2026; these findings may clarify whether the treatment warrants further development or spending. Confirmed
2. Oculis anticipates regulatory clearance to begin Privosegtor trials for acute multiple-sclerosis relapses in the fourth quarter of 2026; clearance remains an expectation, not an approval. Confirmed
3. Track whether operating expenses continue rising and whether cash remains sufficient to support trials, since higher costs could shorten the stated runway or require funding. Analyst inference

Evidence

• Original source link unavailable